Title:
A PHARMACEUTICAL COMPOSITION
Document Type and Number:
WIPO Patent Application WO/2019/017499
Kind Code:
A2
Abstract:
The present invention relates to administration speed of obinutuzumab.
Inventors:
WENGER MICHAEL (CH)
MOBASHER MEHRDAD (US)
LIN CHIN-YU (US)
MOBASHER MEHRDAD (US)
LIN CHIN-YU (US)
Application Number:
PCT/JP2018/038924
Publication Date:
January 24, 2019
Filing Date:
October 19, 2018
Export Citation:
Assignee:
HOFFMANN LA ROCHE (CH)
Domestic Patent References:
| WO2005044859A2 | 2005-05-19 |
Other References:
MOSSNER E; BRUNKER P; MOSER S ET AL.: "Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity", BLOOD, vol. 115, 2010, pages 4393 - 402, XP055190313, DOI: doi:10.1182/blood-2009-06-225979
HERTER S; HERTING F; MUNDIGL O ET AL.: "Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models", MOL CANCER THER, vol. 12, 2013, pages 2031 - 42, XP002739743, DOI: doi:10.1158/1535-7163.MCT-12-1182
TOBINAI K; KLEIN C; OYA N; FINGERLE-ROWSON G.: "A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies", ADV THER, vol. 34, 2017, pages 324 - 56, XP036181746, DOI: doi:10.1007/s12325-016-0451-1
MARCUS R; DAVIES A; ANDO K ET AL.: "Obinutuzumab for the first-line treatment of follicular lymphoma", N ENGL J MED, vol. 377, 2017, pages 1331 - 44
HIDDEMANN W; BARBUI AM; CANALES ALBENDEA MA ET AL.: "Immunochemotherapy with obinutuzumab or rituximab in previously untreated folllicular lymphoma in the randomised phase III GALLIUM study: analysis by chemotherapy regimen", HEMATOL ONCOL, vol. 35, 2017, pages 117 - 9
SEHN LH; CHUA N; MAYER J ET AL.: "Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial", LANCET ONCOL, vol. 17, 2016, pages 1081 - 93, XP029663501, DOI: doi:10.1016/S1470-2045(16)30097-3
HERTER S; HERTING F; MUNDIGL O ET AL.: "Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models", MOL CANCER THER, vol. 12, 2013, pages 2031 - 42, XP002739743, DOI: doi:10.1158/1535-7163.MCT-12-1182
TOBINAI K; KLEIN C; OYA N; FINGERLE-ROWSON G.: "A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies", ADV THER, vol. 34, 2017, pages 324 - 56, XP036181746, DOI: doi:10.1007/s12325-016-0451-1
MARCUS R; DAVIES A; ANDO K ET AL.: "Obinutuzumab for the first-line treatment of follicular lymphoma", N ENGL J MED, vol. 377, 2017, pages 1331 - 44
HIDDEMANN W; BARBUI AM; CANALES ALBENDEA MA ET AL.: "Immunochemotherapy with obinutuzumab or rituximab in previously untreated folllicular lymphoma in the randomised phase III GALLIUM study: analysis by chemotherapy regimen", HEMATOL ONCOL, vol. 35, 2017, pages 117 - 9
SEHN LH; CHUA N; MAYER J ET AL.: "Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial", LANCET ONCOL, vol. 17, 2016, pages 1081 - 93, XP029663501, DOI: doi:10.1016/S1470-2045(16)30097-3
Attorney, Agent or Firm:
SONODA & KOBAYASHI INTELLECTUAL PROPERTY LAW (JP)
Download PDF: